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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1. Introduction 
Infectious retinitis is a potentially devastating cause of permanent visual loss in both 
immunocompetent and immunocompromised patients (1). Infectious retinitis typically presents 
as a posterior uveitis characterized by confluent areas of white retinal necrosis with associated 
retinal haemorrhages. There are multiple etiologies, including, but not limited to: herpes 
simplex virus (HSV); cytomegalovirus (CMV); varicella zoster virus (VZV); and Toxoplasma gondii 
(1). However, cases of dual pathology are seldom reported. Urgent diagnosis and institution of 
proper therapy is needed to improve visual outcomes in all cases of infectious retinitis (1). 
Blindness and visual impairment caused by infectious uveitis can be prevented by early 
identification of the responsible pathogen and prompt treatment accordingly (2). 
In this literature review, we will discuss the reported challenges associated with identifying the 
etiology of infectious retinitis using clinical examination alone. We will also discuss making a 
diagnosis by identifying the causative pathogen, with special consideration given to the 
immunocompromised patient. This of particular relevance to the South African context, due to 
the high prevalence of patients with Human Immunodeficiency Virus (HIV). 
 
2. Limitations of the use of clinical examination alone to identify the cause of infectious 
retinitis 
Several studies have shown that there are disadvantages in using clinical examination alone to 
identify the cause of infectious retinitis. For example, in their 2019 study, Knox et al. found that 
different pathogens may present with a very similar clinical picture (3). This is especially true for 
patients with HIV. In these cases, the retinitis may be atypical compared to the usual 
presentation in their immunocompetent counterparts (3).  
Another 2019 study by del-a-Torre et al. concluded that uveitis secondary to a non-infectious 
cause may also present with similar clinical characteristics and non-specific symptoms (4). It 
was emphasized that multiple differential diagnoses need to be considered when dealing with 
patients with suspected uveitis. This is of particular relevance as immunosuppressive 
medications which are frequently used to treat noninfectious causes of uveitis may not only 
prolong but also worsen an infectious process (5). This leads to the clinician having diagnostic 
doubts (4). It is also important to be aware that different geographical strains of pathogens may 
manifest with varied ocular presentations, depending on the intraocular immune response 
elicited (4). Furthermore, the characteristics of the retinal appearance are often difficult to 
assess due to associated vitreous inflammation, which obscures the view (4). Scheepers et al. 
further discuss the fact that media opacity or poor pupil dilation which frequently occur in 
uveitis secondary to posterior synechiae may mask the clinical features (6). This is another 
disadvantage to using clinical examination alone to identify the cause of the infection.   
 
3. Making a diagnosis 
In their 2013 article, Majumder et al. emphasised that an adapted approach to laboratory 
diagnosis of uveitic cases should be based not only on clinical examination, but should also be 
focused on the patient’s history and specific symptoms as well (7). Only after direct evidence of 
the pathogen in the aqueous or vitreous is identified, can a definitive diagnosis be made. This 
was emphasized by de Groot-Mijnes et al. who suggested that due to similar clinical signs and 
symptoms of patients with uveitis of infectious and non-infectious causes, a distinction 
between these aetiologies based on ocular findings alone is not feasible (5). Matos et al. also 
concluded from their 2007 study that Polymerase Chain Reaction (PCR) is a supplementary 
diagnostic procedure that should be evaluated together with ophthalmological aspects of the 
patient (8). Bodaghi and LeHoang concluded from their 2002 study that diagnostic yield is 
significantly increased when PCR and local antibody production are associated, especially in 
viral infections (9). 
Polymerase chain reaction of intraocular fluids (both aqueous and vitreous) has become 
standard of care to identify the pathogen in infectious retinitis and infective posterior uveitis 
(3), (8). PCR is a reliable investigation that can identify most of the common causes of infection 
(8). This then allows for the clinician to tailor treatment accordingly (3).  
In their 2011 study, Santos et al. analyzed the sensitivity and specificity of real-time PCR to 
detect the etiological agent from blood, plasma, vitreous and aqueous humor and compared 
this with the diagnostic hypothesis (10). They concluded that Real-time PCR was able to detect 
and to confirm diagnostic hypothesis in uveitis. Vitreous humor was found to be the best source 
for molecular diagnosis of infectious uveitis (10). However, aqueous humor samples were also 
found to be appropriate when tested by Real-time PCR (10). This was also illustrated by De 
Groot-Mijnes et al who found that despite the posterior location of infectious retinitis, PCR 
testing of a small volume of aqueous humor revealed a high frequency of positive results with 
no complications (5). 
In their 2013 study, Scheepers et al. reported that routine PCR analysis on intraocular fluid from 
patients presenting with a first episode of suspected active infectious posterior uveitis in a 
population with a high prevalence of human immunodeficiency virus infection were found to be 
valuable (6). They found that PCR testing changed the diagnosis in a quarter of cases (6). Based 
on their findings, it was recommended that PCR analysis of ocular fluids be done early in the 
disease, even in under-resourced settings. When not treated correctly, infections such as these 
can lead to long term complications such as irreversible blindness (6).  
Aqueous and vitreous PCR have been shown to have a high positive (98,7%) and negative 
(67,9%) predictive value in the diagnosis of infectious retinitis (1). These methods are also 




4. Pathogen identification 
Mandelcorn reported in his 2013 article that the more common infectious causes of posterior 
uveitis include syphilis, toxoplasmosis, tuberculosis, endogenous endophthalmitis, and viral 
causes (including herpes simplex virus, herpes zoster virus, and cytomegalovirus) (12). Harper 
et al. reported that patients with vascular or optic nerve inflammation, extensive retinitis, or 
immunocompromise are more likely to have positive PCR results (1).  
It is rare to have more than pathogen identified on a sample. In a large retrospective case-series 
of 433 PCRs on 133 patients, Harper et al. similarly reported only 5 cases of dual-positive PCR. 
Of these dual-positive cases, only 4 (0.92%) were considered to be a true co-infection (1). To 
the best of our knowledge there is currently no published case series on the phenomenon of 
true co-infection in patients with dual-positive PCR.  
When more than one pathogen is isolated it may be misleading. Many clinicians assume that 
the result may be a false positive due to the high sensitivity of the PCR technique. False-
positives can result from sample-to-sample contamination, however a more serious source of 
false-positives is the carryover of DNA from a previous amplification of the same target (13). It 
has also been postulated that certain viruses in dormant states can be liberated in an inflamed 
eye leading to dual-infection (6). Scheepers et al. believed that the false positive results found 
in their study may have been due to previous resolved infection with a small number of “old” 
viruses still being present in the eye. They also suggested that it may have been due to virus in 
the systemic circulation leaking into the eye across a compromised blood ocular barrier, but not 
causing active infection in the eye (6). 
 
5. HIV positive patients 
Patients with HIV are known to present with more than one infectious etiology due to their 
poor immune response.  HIV positive patients with low CD4 counts commonly present with 
multiple concurrent infections. Vago et al. evaluated the frequency and histopathological 
features of concomitant infections of the central nervous system (CNS) with CMV and herpes 
simplex viruses type 1 or 2 (HSV1/2) in a large series of patients who had died from AIDS (14). 
They documented concomitant CMV/HSV central nervous system infections in 16% of patients 
who had died from AIDS (14). Given that the retina is known as an extension of the central 
nervous system both anatomically and developmentally (15), it is plausible that HIV positive 
patients may also have more than 1 concomitant intraocular infection. Similarly, Senya et al. 
demonstrated that 50% of HIV patients hospitalized with an infectious diagnosis had an 
additional concurrent infectious etiology on further investigation (16). It can then be deduced 
that patients with HIV who present with retinitis may present atypically and require a careful 
differential diagnosis. As highlighted in de-la-Torre et al.’s study, making a definite diagnosis 
may be challenging in these cases, as causes may share similar and overlapping clinical 
characteristics (4).  
 
6. Other considerations 
The presence of viral DNA does not necessarily indicate that an organism is causing pathology. 
Epstein-Barr virus (EBV) virus, for example, may remain dormant in both B and T lymphocytes 
and has be shown to be ubiquitous in its distribution in cadaveric tissues (17) as well as in 
aqueous humor of immunocompetent donors (18).  
In their 2015 study, Laaks et al. analysed aqueous PCR results in patients diagnosed 
with undifferentiated uveitis. They documented an increased presence of EBV DNA in ocular 
fluid samples from immunocompromised patients where another infectious agent had been 
identified as the cause of the uveitis (19). They also recommended PCR testing for 
Herpesviridae as a valuable test for patients with undifferentiated uveitis (19). However, 
Ongkosuwito et al.’s 1998 study concluded that testing for EBV does not have to be included in 
the routine management of patients with uveitis, since their study showed no significant 
indications for this virus in the pathogenesis of intraocular inflammation (18). 
 
7. Conclusion 
In reviewing the literature on this topic, it has been found that there are limited studies 
documenting co-infection of patients with retinitis. Although many forms of posterior uveitis 
share similar clinical characteristics, it is of paramount importance to distinguish infectious from 
non-infectious uveitis. More specifically, it is necessary to determine the underlying etiology of 
infectious retinitis as treatment differs accordingly. As highlighted by Scheepers et al. in their 
2013 study, the outcome of incorrectly treated infective uveitis can result in irreversible 
blindness (6).  
Dual positive intraocular fluid polymerase chain reaction is a rare phenomenon which is often 
overlooked. Clinicians need to be aware that, in rare cases, true dual pathology may occur. This 
is of particular importance within the South African context, where a significant portion of the 
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To report 10 cases of dual-positive intraocular fluid PCR results in infectious retinitis where both 
pathogens may be clinically relevant. 
 
Methods 
A retrospective observational case series including 10 patients with infectious retinitis who 




Of 619 patients who underwent intraocular fluid PCR testing for infectious retinitis, we identified 
10 patients (1.62%) where 2 organisms were isolated. All 10 patients were HIV positive with 
profound immunosuppression (mean CD4 count 67cells/mm3) and extensive retinitis. CMV was 
identified in all 10 cases whilst the additional pathogen was VZV in 6 cases, Toxoplasma gondii 
in 3 cases and HSV in 1 case. 
 
Conclusions 
PCR analysis of ocular fluids is important in this clinical scenario since more than one pathogen 
may be present and clinically relevant. Clinicians should be aware of this rare phenomenon to 







Infectious retinitis is a potentially devastating cause of permanent visual loss in both 
immunocompetent and immunocompromised patients.  Causes include herpes simplex virus 
(HSV), cytomegalovirus (CMV), varicella zoster virus (VZV), or Toxoplasma gondii.(1) Urgent 
institution of effective therapy is needed to ensure optimal visual outcomes in these cases.(1) 
However, identification of the causative organism based on clinical examination alone may be 
challenging. The different pathogens may be indistinguishable, particularly in HIV patients where 
the retinitis may be atypical compared to the usual presentation in their immunocompetent 
counterparts.(2) Furthermore, vitritis may obscure the characteristics of the retinitis. Hence it has 
become standard of care in many institutions to investigate infectious retinitis with aqueous or 
vitreous polymerase chain reaction (PCR) to aid in the diagnosis of the pathogen and guide 
treatment selection.(3) 
 
Aqueous and vitreous PCR has a high positive predictive value (98,7%) and negative predictive 
value (67,9%) in the diagnosis of infectious retinitis.(1) It is rare to identify more than one 
pathogen from a single a sample.(1) In such cases it is often assumed that the result is a false 
positive related to the high sensitivity of the PCR technique.(1) We report 10 cases of dual-positive 
intraocular fluid PCR results in infectious retinitis where both pathogens may be clinically 






Patients were identified retrospectively from all intraocular fluid PCR specimens performed for 
infectious retinitis at Groote Schuur Hospital, a university-based referral hospital in Cape Town, 
South Africa.  The database of the National Health Laboratory Service (NHLS) at the hospital was 
used to identify cases between January 2009 and August 2019.  All patients with more than one 
pathogen identified on an intraocular fluid PCR sample were included in the study.  
 
Patients were examined by ophthalmology consultants and registrars at Groote Schuur hospital 
and the initial pre-PCR clinical diagnoses were recorded . Investigations included HIV serology, 
CD4 count, syphilis serology and chest X-ray. Informed consent was taken and vitreous samples 
were obtained by ophthalmology registrars in the outpatient department. Patients received topical 
anaesthesia, followed by cleaning with povidone-iodine 5% solution instilled for more than 3 
minutes prior to the procedure. Adhering to strict aseptic techniques, a sterile lid speculum was 
used and the vitreous sample as well as intravitreal ganciclovir injection was given using a 28-
gauge 12.7mm needle. All patients were phakic, thus the needle insertion site was 4mm from the 
limbus. Povidone-iodine 5% was instilled again following the procedure.  
 
Laboratory detection of HSV, VZV, CMV and Toxoplasma gondii was performed in an ISO 15189 
accredited diagnostic laboratory (Groote Schuur National Health Laboratory Service, Cape Town, 
South Africa).  At various time points during the period described, different nucleic acid isolation 
and PCR methods were used. 
Total nucleic acid isolation from vitreous fluid prior to 1 November 2015 was performed using the 
NucliSens EasyMAG platform (bioMerieux, Boxtel, The Netherlands) according to the 
manufacturer's protocol, and nucleic acid was eluted in 50 µL elution buffer.  From 1 November 
2015 onwards, the Abbott m2000sp (Abbott Laboratories, Abbott Park, Illinois, USA) was used 
according to the manufacturer's protocol, and nucleic acid was eluted in 120 µL elution 
buffer.  Nucleic acid was stored at 4 °C until testing, when 10 µl input volume was used for all in-
house and commercial kit-based PCRs. When in-house end-point nested PCR was used for 
diagnostic testing for each organism, the protocols for each organism were as previously 
described.(4) 
For herpes simplex virus detection, the in-house PCR was used until 1 May 2016; from 1 May 
2016 onwards the RealStar HSV PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) 
was used according to the manufacturer's protocol. For CMV detection, the in-house PCR was 
used until 1 November 2015; from 1 November 2015 onwards the Abbott Realtime CMV kit 
(Abbott Laboratories, Abbott Park, Illinois, USA) was used according to the manufacturer's 
protocol. For varicella zoster virus and Toxoplasma gondii detection, the in-house PCR was used 
throughout the entire time period.(4) Patients with equivocal PCR results  (a value of <62 
international units/mL)  were excluded from the study to limit the possibility of false positives due 
to contamination or replication of dormant organisms.    
 
Treatment of the infectious retinitis was initiated according to the initial clinical diagnosis and then 
tailored according to the results of the PCR. Due to a lack of access to valganciclovir, CMV was 
treated with weekly intravitreal ganciclovir injections.  VZV and HSV were treated with 
intravenous acyclovir, and Toxoplasma gondii was treated with oral co-trimoxazole. Additional 
oral steroids were given at the discretion of the treating ophthalmologist. HIV positive patients 
who were not on antiretrovirals were referred to an HIV physician for initiation of treatment. 
 
The following parameters were recorded: age, sex, HIV status, CD4 count, initial clinical 
diagnosis, time until presentation, visual acuity at presentation, PCR results, complications related 
to vitreous sampling, initial treatment based on clinical diagnosis and alterations in treatment 
according to PCR results. 
 
Ethics approval was obtained from the Human Research Ethics Committee at the University of 
Cape Town (HREC reference number 592/2019). Data analysis was performed using Stata version 
12 statistical software.  Parametric data was presented by means and confidence intervals. Non-





A total of 619 patients underwent intraocular fluid PCR testing for infectious retinitis during this 
time period of which 234 patients (37.8%) had a positive result. Ten patients had more than one 
organism identified on PCR testing and were included in the study.  Thus, these dual-positive cases 
occurred in 1.62% of all cases where PCR was performed and 4.27% of cases where there was a 
positive result on PCR. 
 
Table 1 describes the clinical characteristics and PCR results of the 10 cases. All the patients with 
dual-positive PCR were HIV positive and most were profoundly immunocompromised.  The 
median CD4 count was 21cells/mm3 (range 1-300cells/mm3) and 7 patients (70%) had a CD4 count 
of less than 100cells/mm3. Three patients (30%) were on antiretroviral treatment at the time of 
presentation.  
 
The mean age was 32,9 years (95% CI [26.96, 38.83]). Nine out of 10 cases (90%) were female. 
The average time between onset of symptoms and presentation was 4.1 weeks (2 days – 8 weeks). 
Five cases demonstrated bilateral involvement (50%). One patient (case 9) had no visual acuities 
documented at presentation. The presenting best corrected Snellen visual acuity of the remaining 
13 involved eye/-s ranged from 6/9 to perception of light, with 7 eyes (53.8%) presenting with a 
visual acuity of counting fingers or worse. All except one of the patients had an initial clinical 
diagnosis of CMV retinitis. The other patient was diagnosed as posterior uveitis of uncertain 
aetiology and although CMV retinitis was considered in the differential diagnosis it was thought 
to be less likely as this patient had a CD4 count of 300cells/mm3.   
 
PCR revealed CMV as one of the pathogens in all 10 cases.  The additional pathogen was VZV in 
6 cases (60%), Toxoplasma gondii in 3 cases (30%) and HSV in 1 case (10%). One patient (case 
number 8) had dual-positive PCR for CMV and VZV demonstrated on 2 separate specimens at the 
same presentation.  Similarly, one patient (case number 3) had CMV and Toxoplasma gondii 
confirmed on PCR at original presentation, which was treated with intravitreal ganciclovir 
injections and oral co-trimoxazole.  Ten months later the patient represented with a posterior 
uveitis and again was found to have CMV and Toxoplasma gondii on vitreous PCR. 
 
Treatment was adjusted to include the additional organism identified on PCR and all eyes 
responded to treatment. The duration of follow up ranged from 2 weeks to 26 months (mean 8.5 
months). No complications related to vitreous fluid aspiration procedures were identified and no 




                  
 
Figure 1:  Fundus photograph of the left eye of case nr 6.  A 42-year-old female. HIV positive with 
CD4 count of 1 cell/mm3. Diagnosed as CMV retinitis on presentation. PCR showed CMV+ and 
VZV+. 
 
                  
Table 1: Patient characteristics and PCR results 
 






Laterality Presenting Snellen Visual 
Acuity in Affected Eye/-s 
PCR Positive 
Results 
1 39 Female Positive 53 CMV Retinitis Right HM CMV + Toxo 
2 30 Female Positive 9 CMV Retinitis Left 6/18 CMV + VZV 
3 50 Male Positive 130 CMV Retinitis Bilateral CF both eyes CMV + Toxo 
4 28 Female Positive 79 CMV Retinitis Bilateral Right 6/18 
Left NPL 
CMV + Toxo 
5 31 Female Positive 21 CMV Retinitis Right PL CMV + HSV 
6 42 Female Positive 1 CMV Retinitis Left PL CMV + VZV 
7 28 Female Positive 300 Posterior uveitis 
?cause 
Right 6/24 CMV + VZV 
8 31 Female Positive 2 CMV retinitis Bilateral Right 6/9 
Left 6/18 
CMV + VZV 
9 28 Female Positive Not done CMV retinitis Bilateral Unknown CMV + VZV 
10 22 Female Positive 12 CMV retinitis Bilateral Right NPL 
Left 6/60 
CMV + VZV 
 
NPL: Nil perception of light, PL: Perception of light, HM: Hand movements, CF: Counting fingers 
CMV: Cytomegalovirus, Toxo: Toxoplasma gondii, VZV: Varicella zoster virus, HSV: Herpes simplex virus 
Discussion 
 
We report 10 cases of infectious retinitis with more than one organism identified on vitreous 
PCR.  This is a rare occurrence (1.42% of all PCRs performed for infectious retinitis at our 
institution).  In a large retrospective case-series of 433 PCRs on 133 patients, Harper et al. 
similarly reported only 5 cases of dual-positive PCR of which 4 (0.92%) were considered true co-
infection.(1)  To the best of our knowledge in the English literature to date, our case series is the 
largest identifying potential co-infection on ocular fluid PCR. 
 
Previously it has been assumed that the second organism identified on PCR is a false positive result 
related to the high sensitivity of the PCR technique.(1) It is notable that all the patients in our case 
series were HIV positive with profound immunosuppression and presented with extensive retinitis. 
We propose that, in this specific clinical scenario, dual-positive PCRs should be considered as true 
co-infection. 
 
False positive results would be expected also to occur in HIV negative patients and HIV positive 
patients with higher CD4 counts.  HIV positive patients with low CD4 counts commonly present 
with multiple concurrent infections. Vago et al. documented  concomitant CMV/HSV central 
nervous system infections in 16% of patients who had died from AIDS.(5) Similarly Senya et al. 
demonstrated that 50% of HIV patients hospitalized with an infectious diagnosis had an additional 
concurrent infectious aetiology on further investigation.(6) Therefore it is not unexpected that the 
dual-positive patients in this case series were all HIV positive with low CD4 counts.   
   
Additionally, two cases had dual positive PCR’s confirmed on more than one occasion which 
reduces the possibility of the results being false positives due to contamination. Case number 8 
was clinically diagnosed as bilateral CMV retinitis. Vitreous tap PCR was positive for CMV and 
VZV. Due to the dual positive result the vitreous tap was repeated 4 days later and the PCR was 
again positive for both. Similarly, case number 3 was clinically diagnosed as bilateral CMV 
retinitis. The PCR was positive on the right eye for Toxoplasma gondii, and positive on the left 
eye for CMV and Toxoplasma gondii. Ten months after successful treatment for both organisms, 
it was noted that the retinitis reactivated in the right eye.  Vitreous tap of the right eye was now 
positive for CMV as well as Toxoplasma gondii.  
 
The presence of viral DNA does not necessarily indicate that an organism is causing pathology. 
Epstein-Barr virus (EBV) virus, for example, may remain dormant in both B and T lymphocytes 
and has be shown to be ubiquitous in its distribution in cadaveric tissues(7) as well as in aqueous 
humor of immunocompetent donors.(8) Laaks et al. documented an increased presence of Epstein–
Barr virus DNA in ocular fluid samples from immunocompromised patients where another 
infectious agent had been identified as the cause of the uveitis.(9) Therefore, EBV PCR testing 
was not performed in our patients. 
 
In immunocompromised patients CMV, HSV, VZV and Toxoplasma gondii may all present with 
clinically indistinguishable atypical retinitis.  Ocular fluid PCR may provide specific aetiological 
orientation and guide treatment.(1, 10) In the presence of dual-positive PCRs where both 
organisms could be causative and require different treatment strategies, management becomes 
more difficult.  Although repeating the sample would be judicious, delay in instituting early 
treatment may result in permanent visual loss. Therefore, it may be prudent to initiate treatment to 
cover both organisms from the outset.   
 
Limitations include the small size and retrospective nature of our case series. Furthermore, a 
percentage of the PCR results could still be false positives.  Larger, multicentric studies are needed 
to better evaluate this rare phenomenon and establish its true prevalence.  
 
In conclusion, this case series has shown that more than one pathogen may be present and clinically 
relevant in significantly immunocompromised HIV positive patients with infectious retinitis. It is 
important for clinicians to be aware of this rare phenomenon to ensure that, when it does occur, 
consideration be given to adjusting treatment to cover both pathogens. 
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Patient characteristics and PCR results 
 






Laterality Presenting Snellen Visual 
Acuity in Affected Eye/-s 
PCR Positive 
Results 
1 39 Female Positive 53 CMV Retinitis Right HM CMV + Toxo 
2 30 Female Positive 9 CMV Retinitis Left 6/18 CMV + VZV 
3 50 Male Positive 130 CMV Retinitis Bilateral CF both eyes CMV + Toxo 
4 28 Female Positive 79 CMV Retinitis Bilateral Right 6/18 
Left NPL 
CMV + Toxo 
5 31 Female Positive 21 CMV Retinitis Right PL CMV + HSV 
6 42 Female Positive 1 CMV Retinitis Left PL CMV + VZV 
7 28 Female Positive 300 Posterior uveitis 
?cause 
Right 6/24 CMV + VZV 
8 31 Female Positive 2 CMV retinitis Bilateral Right 6/9 
Left 6/18 
CMV + VZV 
9 28 Female Positive Not done CMV retinitis Bilateral Unknown CMV + VZV 
10 22 Female Positive 12 CMV retinitis Bilateral Right NPL 
Left 6/60 
CMV + VZV 
 
NPL: Nil perception of light, PL: Perception of light, HM: Hand movements, CF: Counting fingers 
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